Skip to main content

Advertisement

SpringerLink
Log in

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Serotonin (5-HT)2C receptors are implicated in the control of mood, and their blockade is of potential interest for the management of anxiodepressive states.

Objectives

Herein, we characterized the in vitro and in vivo pharmacological profile of the novel benzourea derivative, S32006.

Materials and methods

Standard cellular, electrophysiological, neurochemical, and behavioral procedures were used.

Results

S32006 displayed high affinity for human (h)5-HT2C and h5-HT2B receptors (pK is, 8.4 and 8.0, respectively). By contrast, it had negligible (100-fold lower) affinity for h5-HT2A receptors and all other sites examined. In measures of Gq-protein coupling/phospholipase C activation, S32006 displayed potent antagonist properties at h5-HT2C receptors (pK B values, 8.8/8.2) and h5-HT2B receptors (7.8/7.7). In vivo, S32006 dose-dependently (2.5–40.0 mg/kg, i.p. and p.o.) abolished the induction of penile erections and a discriminative stimulus by the 5-HT2C receptor agonist, Ro60,0175, in rats. It elevated dialysis levels of noradrenaline and dopamine in the frontal cortex of freely moving rats, and accelerated the firing rate of ventrotegmental dopaminergic and locus ceruleus adrenergic neurons. At similar doses, S32006 decreased immobility in a forced-swim test in rats, reduced the motor depression elicited by 5-HT2C and α2-adrenoceptor agonists, and inhibited both aggressive and marble-burying behavior in mice. Supporting antidepressant properties, chronic (2–5 weeks) administration of S32006 suppressed “anhedonia” in a chronic mild stress procedure and increased both expression of BDNF and cell proliferation in rat dentate gyrus. Finally, S32006 (0.63–40 mg/kg, i.p. and p.o) displayed anxiolytic properties in Vogel conflict and social interaction tests in rats.

Conclusion

S32006 is a potent 5-HT2C receptor antagonist, and possesses antidepressant and anxiolytic properties in diverse rodent models.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

Similar content being viewed by others

References

  • Alex KD, Pehek EA (2007) Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113:296–320

    PubMed  CAS  Google Scholar 

  • Alves SH, Pinheiro G, Motta V, Landeira-Fernandez J, Cruz APM (2004) Anxiogenic effects in the rat elevated plus-maze of 5-HT2C agonists into ventral but not dorsal hippocampus. Behav Pharmacol 15:37–43

    PubMed  CAS  Google Scholar 

  • Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S (2001) Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 4:399–408

    PubMed  CAS  Google Scholar 

  • Bakish D, Lapierre YD, Weinstein R, Klein J, Wiens A, Jones B, Horn E, Browne M, Bourget D, Blanchard A et al (1993) Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder. J Clin Psychopharmacol 13:409–414

    PubMed  CAS  Google Scholar 

  • Banasr M, Hery M, Printemps R, Datzuta A (2004) Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology 29:450–460

    PubMed  CAS  Google Scholar 

  • Banasr M, Soumier A, Hery M, Mocaër E, Daszuta A (2006) Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 59:1087–1096

    PubMed  CAS  Google Scholar 

  • Bancila M, Vergé D, Rampin O, Backstrom JR, Sanders-Bush E, McKenna KE, Marson L, Calas A, Giuliano F (1999) 5-HT2C receptors on spinal neurons controlling penile erection in the rat. Neuroscience 92:1523–1537

    PubMed  CAS  Google Scholar 

  • Berg KA, Harvey JA, Spampinato U, Clarke WP (2005) Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors. Trends Pharmacol Sci 26:625–630

    PubMed  CAS  Google Scholar 

  • Blier P, De Montigny C (1998) Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry 44:313–323

    PubMed  CAS  Google Scholar 

  • Boothman L, Raley J, Denk F, Hirani E, Sharp T (2006) In vivo evidence that 5-HT2C receptors inhibit 5-HT neuronal activity via a GABAergic mechanism. Br J Pharmacol 149:861–869

    PubMed  CAS  Google Scholar 

  • Bristow LJ, O’Connor D, Watts R, Duxon MS, Hutson PH (2000) Evidence for accelerated desensitisation of 5-HT2C receptors following combined treatment with fluoxetine and the 5-HT1A receptor antagonist, WAY100,635, in the rat. Neuropsychopharmacology 39:1222–1236

    CAS  Google Scholar 

  • Brocco M, Dekeyne A, Veiga S, Girardon S, Millan MJ (2002) Induction of locomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agent. Pharmacol Biochem Behav 71:667–680

    PubMed  CAS  Google Scholar 

  • Brocco M, Dekeyne A, Papp M, Millan MJ (2006) Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol 17:559–572

    PubMed  CAS  Google Scholar 

  • Bubar MJ, Cunningham KA (2007) Distribution of serotonin 5-HT2C receptors in the ventral tegmental area. Neuroscience 146:286–297

    PubMed  CAS  Google Scholar 

  • Campbell BM, Merchant KM (2003) Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. Brain Res 993:1–9

    PubMed  CAS  Google Scholar 

  • Castren E, Voikar V, Rantamaki T (2007) Role of neurotrophic factors in depression. Curr Opin Pharmacol 7:18–21

    PubMed  CAS  Google Scholar 

  • Cespuglio R, Rousset C, Debilly G, Rochat C, Millan MJ (2005) Acute administration of the novel serotonin and noradrenaline reuptake inhibitor, S33005, markedly modifies sleep–wake cycle architecture in the rat. Psychopharmacology 181:639–652

    PubMed  CAS  Google Scholar 

  • Chanrion B, Mannoury la Cour C, Gavarini S, Seimandi M, Vincent L, Pujol JF, Bockaert J, Marin P, Millan MJ (2008) Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-HT2C receptors: differential modulation of cell surface expression and signal transduction. Mol Pharmacol 73:748–757

    PubMed  CAS  Google Scholar 

  • Clemett DA, Punhani T, Duxon MS, Blackburn TP, Fone KC (2000) Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology 39:123–132

    PubMed  CAS  Google Scholar 

  • Clenet F, De Vos A, Bourin M (2001) Involvement of 5-HT2C receptors in the anti-immobility effects of antidepressants in the forced swimming test in mice. Eur Neuropsychopharmacol 11:145–152

    PubMed  CAS  Google Scholar 

  • Coppell AL, Pei Q, Zetterström TSC (2003) Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 44:903–910

    PubMed  CAS  Google Scholar 

  • Cowen PJ (1998) Pharmacological challenge tests and brain serotonin function in depression during SSRI treatment. In: Briley M, Montgomery S (eds) Antidepressant therapy at the dawn of third millennium. Martin Dunitz Ltd, London, pp 175–189

    Google Scholar 

  • Cremers TI, Rea K, Bosker FJ, Wikström HV, Hogg S, Mørk A, Westerink BH (2007) Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: mechanistic studies. Neuropsychopharmacology 32:1550–1557

    PubMed  CAS  Google Scholar 

  • Cryan JF, Lucki I (2000) Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine2C receptors. J Pharm Exp Ther 295:1120–1126

    CAS  Google Scholar 

  • Cussac D, Newman-Tancredi A, Duqueyroix D, Pasteau V, Millan MJ (2002) Differential activation of Gq/11 and Gi3 proteins as 5-hydroxytryptamine2C receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. Mol Pharmacol 62:578–586

    PubMed  CAS  Google Scholar 

  • De Deurwaerdère P, Spampinato U (2001) The nigrostriatal dopamine system: a neglected target for 5-HT2C receptors. Trends Pharmacol Sci 22:502–503

    PubMed  Google Scholar 

  • De Foubert G, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA, Murray TK, Gaillard JP, Deville C, Xhenseval V, Thomas CE, O’Neill MJ, Zetterström TSC (2004) Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 128:597–604

    PubMed  Google Scholar 

  • De Jong TR, Veening JG, Waldinger MD, Cools AR, Olivier B (2006) Serotonin and the neurobiology of the ejaculatory threshold. Neurosci Biobehav Rev 30:893–907

    PubMed  Google Scholar 

  • De Vry J, Benz U, Schreiber R, Traber J (1993) Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. Eur J Pharmacol 249:331–339

    PubMed  Google Scholar 

  • Dekeyne A, Girardon S, Millan MJ (1999) Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, Ro 60-0175: a pharmacological analysis. Neuropharmacology 38:415–423

    PubMed  CAS  Google Scholar 

  • Dekeyne A, Denorme B, Monneyron S, Millan MJ (2000) Citalopram reduces social interaction in rats by activation of serotonin (5-HT)2C receptors. Neuropharmacology 39:1114–1117

    PubMed  CAS  Google Scholar 

  • Descamps-Lefebvre A, Rousset C, Millan MJ, Spedding M, Delagrange P, Cespuglio R (2008) Effects of agomelatine, a MT1/MT2 agonist and 5-HT2C antagonist, on 24-hour electroencephalogram in the rat. Soc Neurosci Abstr P501.17

  • Di Giovanni G, De Deurwaerdere P, Di Mascio M, Di Matteo V, Esposito E, Spampinato U (1999) Selective blockade of serotonin2C/2B receptors enhances mesolimbic and mesocortical dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 91:587–597

    PubMed  Google Scholar 

  • Di Giovanni G, Di Matteo V, Pierucci M, Benigno A, Esposito E (2006) Central serotonin2C receptor: from physiology to pathology. Curr Topics Med Chem 6:1909–1925

    Google Scholar 

  • Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59:1116–1127

    PubMed  CAS  Google Scholar 

  • Dunlop J, Sabb AL, Mazandarani H, Zhang J, Kalgaonker S, Shukhina E, Sukoff S, Vogel RL, Stack G, Schechter L, Harrison BL, Rosenzweig-Lipson SJ (2005) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. Pharmacol Exp Ther 313:862–869

    CAS  Google Scholar 

  • Dutton AC, Barnes NM (2006) Anti-obesity pharmacotherapy: future perspectives utilising 5-HT2C receptor agonists. Drug Disc Today: Therapeutic Strategies 3:577–583

    Google Scholar 

  • Duxon MS, Flanigan TP, Reavley AC, Baxter GS, Blackburn TP, Fone KC (1997) Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system. Neuroscience 76:323–329

    PubMed  CAS  Google Scholar 

  • Erzegovesi S, Martucci L, Henin M, Bellodi L (2001) Low versus standard dose mCPP challenge in obsessive-compulsive patients. Neuropsychopharmacology 24:31–36

    PubMed  CAS  Google Scholar 

  • File SE, Seth P (2003) A review of 25 years of the social interaction test. Eur J Pharm 463:35–53

    CAS  Google Scholar 

  • Fone KC, Shalders K, Fox ZD, Arthur R, Marsden CA (1996) Increased 5-HT2C receptor responsiveness occurs on rearing rats in social isolation. Psychopharmacology 123:346–352

    PubMed  CAS  Google Scholar 

  • Gatch MB (2003) Discriminative stimulus effects of m-chlorophenylpiperazine as a model of the role of serotonin receptors in anxiety. Life Sci 73:1347–1367

    PubMed  CAS  Google Scholar 

  • Giorgetti M, Tecott LH (2004) Contributions of 5-HT2C receptors to multiple actions of central serotonin systems. Eur J Pharmacol 488:1–9

    PubMed  CAS  Google Scholar 

  • Gleason SD, Lucaites VL, Shannon HE, Nelson DL, Leander JD (2001) m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT2C receptors but not 5-HT2A or 5-HT2B receptors. Behav Pharmacol 12:613–620

    PubMed  CAS  Google Scholar 

  • Gobert A, Rivet JP, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP, Cistarelli L, Melon C, Millan MJ (2000) Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36:205–221

    PubMed  CAS  Google Scholar 

  • Graeff FG (2004) Serotonin, the periaqueductal gray and panic. Neurosci Biobehav Rev 28:239–259

    PubMed  CAS  Google Scholar 

  • Griebel G, Perrault G, Sanger DJ (1997) A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology 36:793–802

    PubMed  CAS  Google Scholar 

  • Grillon C, Levenson J, Pine DS (2007) A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study. Neuropsychopharmacology 32:225–231

    PubMed  CAS  Google Scholar 

  • Hackler EA, Turner GH, Gresch PJ, Sengupta S, Deutch AY, Avison MJ, Gore JC, Sanders-Bush E (2007) 5-Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-b-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation. J Pharm Exp Ther 320:1023–1029

    CAS  Google Scholar 

  • Harada K, Aota M, Inoue T, Matsuda R, Mihara T, Yamaji T, Ishibashi K, Matsuoka N (2006) Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone. Eur J Pharmacol 553:171–184

    PubMed  CAS  Google Scholar 

  • Heisler LK, Zhou L, Bajwa P, Hsu J, Tecott LH (2007) Serotonin 5-HT2C receptors regulate anxiety-like behavior. Genes Brain Behav 6:491–496

    PubMed  CAS  Google Scholar 

  • Heslop KE, Curzon G (1999) Effect of reserpine on behavioural responses to agonists at 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT2C receptor subtypes. Neuropharmacology 38:883–891

    PubMed  CAS  Google Scholar 

  • Hirschfeld RMA (2003) Long-term side effects of SSRIs: sexual dysfunction and weight gain. J Clin Psychiatry 64:20–24

    Article  PubMed  CAS  Google Scholar 

  • Hull EM, Muschamp JW, Sato S (2004) Dopamine and serotonin: influences on male sexual behavior. Physiol Behav 83:291–307

    PubMed  CAS  Google Scholar 

  • Ichimaru Y, Egawa T, Sawa A (1995) 5-HT1A-receptor subtype mediates the effect of fluvoxamine, selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol 68:65–70

    PubMed  CAS  Google Scholar 

  • Invernizzi RW, Pieruci M, Calcagno E, Di Giovanni G, Di Matteo V, Benigno A, Esposito E (2007) Selective activation of the 5-HT2C receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: a combined in vivo electrophysiological and neurochemical study. Neuroscience 144:1523–1535

    PubMed  CAS  Google Scholar 

  • Iwamoto K, Nakatani N, Bundo M, Yoshikawa T, Kato T (2005) Altered RNA editing of serotonin 2C receptor in a rat model of depression. Neurosci Res 53:69–76

    PubMed  CAS  Google Scholar 

  • Jenck F, Moreau J-L Berendsen HHG, Boes M, Broekkamp CLE, Martin JR, Wichmann J, Van Delft AML (1998) Antiaversive effects of 5-HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol 8:161–168

    PubMed  CAS  Google Scholar 

  • Kantor S, Jakus R, Balogh B, Benko A, Bagdy G (2004) Increased wakefulness, motor activity and decreased theta activity after blockade of the 5-HT2B receptor by the subtype-selective antagonist SB-215505. Br J Pharmacol 142:1332–1342

    PubMed  CAS  Google Scholar 

  • Kantor S, Jakus R, Molnar E, Gyongyosi N, Toth A, Detari L, Bagdy G (2005) Despite similar anxiolytic potential, the 5-HT2C receptor antagonist SB-242084 and chlordiazepoxide produced differential effects on EEG power spectra. J Pharm Exp Ther 315:921–930

    CAS  Google Scholar 

  • Kempermann G, Wiskott L, Gage FH (2004) Functionnal significance of adult neurogenesis. Curr Opin Neurobiol 14:186–191

    PubMed  CAS  Google Scholar 

  • Kennett GA, Lightowler S, De Biasi V, Stevens NC, Wood MD, Tulloch IF, Blackburn TP (1994) Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology 33:1581–1588

    PubMed  CAS  Google Scholar 

  • Kennett GA, Bright F, Trail B, Baxter GS, Blackburn TP (1996a) Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety. Br J Pharmacol 117:1443–1448

    PubMed  CAS  Google Scholar 

  • Kennett GA, Wood MD, Bright F, Cilia J, Piper DC, Gager T, Thomas D, Baxter GS, Forbes IT, Ham P, Blackburn TP (1996b) In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 117:427–434

    PubMed  CAS  Google Scholar 

  • Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP (1997) SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36:609–620

    PubMed  CAS  Google Scholar 

  • Kennett GA, Lightowler S, Trail B Bright F, Bromidge S (2000) Effects of RO 60 0175, a 5-HT2C receptor agonist, in three animal models of anxiety. Eur J Pharm 387:197–204

    CAS  Google Scholar 

  • Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519–526

    PubMed  CAS  Google Scholar 

  • Launay JM, Hervé P, Peoc’h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L (2002) Function of the serotonin 5-hydroxytryptamine2B receptor in pulmonary hypertension. Nat Med 8:1129–1135

    PubMed  CAS  Google Scholar 

  • Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20:9104–9110

    PubMed  CAS  Google Scholar 

  • Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S (2007) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: a novel 5-hydroxytryptamine2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 320:486–496

    PubMed  CAS  Google Scholar 

  • Martin JR, Bös M, Jenck F, Moreau J, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HH, Broekkamp CL, Ruigt GS, Köhler C, Delft AM (1998) 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913–924

    PubMed  CAS  Google Scholar 

  • Martin JP, Ballard TM, Higgins GA (2002) Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol Biochem Behav 71:615–625

    PubMed  CAS  Google Scholar 

  • Menard J, Treit D (1999) Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci Biobehav Rev 23:591–613

    PubMed  CAS  Google Scholar 

  • Micallef J, Blin O (2001) Neurobiology and clinical pharmacology of obsessive–compulsive disorder. Clin Neuropharmacol 24:191–207

    PubMed  CAS  Google Scholar 

  • Miczek KA, O’Donnell JM (1978) Intruder-evoked aggression in isolated and nonisolated mice: effects of psychomotor stimulants and l-dopa. Psychopharmacology 57:47–55

    PubMed  CAS  Google Scholar 

  • Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:53–244

    Google Scholar 

  • Millan MJ (2005) 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 60:441–460

    Article  PubMed  Google Scholar 

  • Millan MJ (2006) Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 110:135–370

    PubMed  CAS  Google Scholar 

  • Millan MJ, Brocco M (2003) The Vogel conflict test: procedural aspects, γ-aminobutyric acid, glutamate and monoamines. Eur J Pharmacol 463:67–96

    PubMed  CAS  Google Scholar 

  • Millan MJ, Peglion JL, Lavielle G, Perrin-Monneyron S (1997a) 5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. Eur J Pharmacol 325:9–12

    PubMed  CAS  Google Scholar 

  • Millan MJ, Hjorth S, Samanin R, Schreiber R, Jaffard R, De Ladonchamps B, Veiga S, Goument B, Peglion JL, Spedding M, Brocco M (1997b) S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties. J Pharmacol Exp Ther 282:148–161

    PubMed  CAS  Google Scholar 

  • Millan MJ, Dekeyne A, Gobert A (1998) Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37:953–955

    PubMed  CAS  Google Scholar 

  • Millan MJ, Gobert A, Rivet J-M, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F (2000a) Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of a2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci 12:1079–1095

    PubMed  CAS  Google Scholar 

  • Millan MJ, Lejeune F, Gobert A (2000b) Reciprocal autoreceptor and heteroceptor control of serotonergic, dopaminergic and adrenergic transmission in frontal cortex: a review, and relevance to the actions of antidepressant agents. J Psychopharmacol 14:114–138

    Article  PubMed  CAS  Google Scholar 

  • Millan MJ, Dekeyne A, Papp M, Drieu La Rochelle C, Macsweeny C, Peglion J-L, Brocco M (2001) S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram and clomipramine. J Pharm Exp Ther 298:581–591

    CAS  Google Scholar 

  • Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D (2003) The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-HT2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 306:954–964

    PubMed  CAS  Google Scholar 

  • Millan MJ, Brocco M, Gobert A, Dekeyne A (2005) Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology 17:448–458

    Google Scholar 

  • Millan MJ, Loiseau F, Dekeyne A, Gobert A, Flik G, Cremers TI, Rivet JM, Sicard D, Billiras R, Brocco M (2007) S33138, a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. III. Actions in models of therapeutic activity and induction of side-effects. J Pharmacol Exp Ther 324:1212–1226

    PubMed  Google Scholar 

  • Mitchell PJ (2005) Antidepressant treatment and rodent aggressive behaviour. Eur J Pharmacol 526:147–162

    PubMed  CAS  Google Scholar 

  • Mitchell PJ, Fairhall SJ, Fletcher A, Redfern PH (2003) Effects of single and repeated electroconvulsive shock on the social and agonistic behaviour of resident rats. Neuropharmacology 44:911–925

    PubMed  CAS  Google Scholar 

  • Molewijk HE, van der Poel AM, Mos J, van der Heyden JA, Olivier B (1995) Conditioned ultrasonic distress vocalizations in adult male rats as a behavioural paradigm for screening anti-panic drugs. Psychopharmacology 117:32–40

    PubMed  CAS  Google Scholar 

  • Moreau JL, Jenck F, Martin JR, Perrin S, Haefely WE (1993) Effects of repeated mild stress and two antidepressant treatments on the behavioural response to 5-HT1C receptor activation in rats. Psychopharmacology 110:140–144

    PubMed  CAS  Google Scholar 

  • Moreau JL, Bös M, Jenck F, Martin JR, Mortas P, Wichmann J (1996) 5-HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. Eur Neuropsychopharmacol 6:169–175

    PubMed  CAS  Google Scholar 

  • Moya PR, Berg KA, Gutiérrez-Hernandez MA, Sáez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP (2007) Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Pharmacol Exp Ther 321:1054–1061

    PubMed  CAS  Google Scholar 

  • Murphy DL, Mueller EA, Hill JL, Tolliver TJ, Jacobsen FM (1989) Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology 98:275–282

    PubMed  CAS  Google Scholar 

  • Nebigil CG, Maroteaux L (2003) Functional consequence of serotonin/5-HT2B receptor signaling in heart: role of mitochondria in transition between hypertrophy and heart failure? Circulation 108:902–908

    PubMed  Google Scholar 

  • Nestler EJ, Carlezon WA Jr (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59:1151–1159

    PubMed  CAS  Google Scholar 

  • Nicolas LB, Kolb Y, Prinssen EP (2006) A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants. Eur J Pharmacol 547:106–115

    PubMed  CAS  Google Scholar 

  • Olié JP, Kasper S (2007) Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10:661–673

    PubMed  Google Scholar 

  • Papp M, Gruca P, Boyer PA, Mocaër E (2003) Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28:694–703

    PubMed  CAS  Google Scholar 

  • Papp M, Litwa E, Gruca P, Mocaër E (2006) Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol 17:9–18

    PubMed  CAS  Google Scholar 

  • Rosenzweig-Lipson S, Sabb A, Stack G, Mitchell P, Lucki I, Malberg JE, Grauer S, Brennan J, Cryan JF, Sukoff Rizzo SJ, Dunlop J, Barrett JE, Marquis KL (2007) Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. Psychopharmacology 192:159–70

    PubMed  CAS  Google Scholar 

  • Sabbe B, Hulstijn W, Maes M, Pier M, Scharpé S, Zitman F (2001) Psychomotor slowing, neuroendocrine responses, and behavioural changes after oral administration of meta-chlorophenylpiperazine in normal volunteers. Psychiatry Res 105:151–163

    PubMed  CAS  Google Scholar 

  • Sánchez C, Meier E (1997) Behavioural profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology 129:197–205

    PubMed  Google Scholar 

  • Sanders-Bush E, Fentress H, Hazelwood L (2003) Serotonin 5-HT2C receptors: molecular and genomic diversity. Mol Interv 3:319–330

    PubMed  CAS  Google Scholar 

  • Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L (2003) Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol 140:277–284 2003 Sep

    PubMed  CAS  Google Scholar 

  • Sharma A, Punhani F, Fone KCF (1997) Distribution of the 5-hydroxytryptamine2C receptor protein in adult rat brain and spinal cord determined using a receptor-directed antibody effect of 5,7-dihydroxytryptamine. Synapse 26:45–56

    Google Scholar 

  • Singewald N, Sharp T (2000) Neuroanatomical targets of anxiogenic drugs in the hindbrain as revealed by Fos immunocytochemistry. Neuroscience 98:759–770

    PubMed  CAS  Google Scholar 

  • Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R, Patterson T, Seymour PA, Swick A, Iredale PA (2007) CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 52:279–290

    PubMed  CAS  Google Scholar 

  • Smith MI, Piper DC, Duxon MS, Upton N (2002) Effect of SB-243213, a selective 5-HT2C receptor antagonist, on the rat sleep profile: a comparison to paroxetine. Pharmacol Biochem Behav 71:599–605

    PubMed  CAS  Google Scholar 

  • Somerville EM, Horwood JM, Lee MD, Kennett GA, Clifton PG (2007) 5-HT2C receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice. Eur J Neurosci 25:3115–3124

    PubMed  Google Scholar 

  • Stark JA, Davies KE, Williams SR, Luckman SM (2006) Functional magnetic resonance imaging and c-fos mapping in rats following an anorectic dose of m-chlorophenylpiperazine. NeuroImage 31:1228–1237

    PubMed  Google Scholar 

  • Tanda G, Carboni E, Frau R, Di Chiara G (1994) Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology 115:285–288

    PubMed  CAS  Google Scholar 

  • Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D (1995) Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 374:542–546

    PubMed  CAS  Google Scholar 

  • Tremblay P, Blier P (2006) Catecholaminergic strategies for the treatment of major depression. Curr Drug Targets 7:149–158

    PubMed  CAS  Google Scholar 

  • Van Oekelen D, Luyten WH, Leysen JE (2003) 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 72:2429–2449

    PubMed  Google Scholar 

  • Van Veen JF, Van der Wee NJA, Fiselier J Van Vliet IM, Westenberg HGM (2007) Behavioural effects of rapid intravenous administration of meta-chlorophenyl piperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy control. Eur Neuropsychopharmacol 17:637–642

    PubMed  Google Scholar 

  • Walker EA, Kohut SJ, Hass RW Brown EK, Prabandham A, Lefever T (2005) Selective and nonselective serotonin antagonists block the aversive stimulus properties of MK212 and m-chlorophenylpiperazine (mCPP) in mice. Neuropharmacology 42:1210–1219

    Google Scholar 

  • Willner P (1997) Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 134:319–329

    PubMed  CAS  Google Scholar 

  • Winter JC, Rabin RA (1993) Discriminative stimulus properties of m-chlorophenylpiperazine. Pharmacol Biochem Behav 45:221–223

    PubMed  CAS  Google Scholar 

  • Wood MD, Reavill C, Trail B, Wilson A, Stean T, Kennett GA, Lightowler S, Blackburn TP, Thomas D, Gager TL, Riley G, Holland V, Bromidge SM, Forbes IT, Middlemiss DN (2001) SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology 41:186–199

    PubMed  CAS  Google Scholar 

  • Zacharko RM, Koszycki D, Mendella PD, Bradwejn J (1995) Behavioral, neurochemical, anatomical and electrophysiological correlates of panic disorder: multiple transmitter interaction and neuropeptide colocalization. Prog Neurobiol 47:371–423

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank Manuelle Touzard, Sylvie Girardon, Sylvie Veiga, Huguette Gressier, Brigitte Denorme, Loretta Iob Laetitia Cistarelli, Rodolphe Billiras, and Jimmy Mullot for excellent technical assistance.

Author information

Authors and Affiliations

  1. Department of Psychopharmacology, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 chemin de Ronde, 78290, Croissy/Seine, France

    Anne Dekeyne, Clotilde Mannoury la Cour, Alain Gobert, Mauricette Brocco, Françoise Lejeune, Jean-Michel Rivet & Mark J. Millan

  2. Department of Pharmacology, Oxford University, Mansfield Road, Oxford, OX1 3QT, UK

    Florence Serres & Trevor Sharp

  3. IC2N, IBDML, UMR-6216 CNRS-Université de la méditerranée, Campus de Luminy-Case 907, 13288, Marseille cedex 9, France

    Annie Daszuta & Amélie Soumier

  4. Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna St., 31-343, Krakow, Poland

    Mariusz Papp

  5. Brains-on-Line, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands

    Gunnar Flik & Thomas I. Cremers

  6. Department of Chemistry F, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 chemin de Ronde, 78290, Croissy/Seine, France

    Olivier Muller & Gilbert Lavielle

Authors
  1. Anne Dekeyne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Clotilde Mannoury la Cour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alain Gobert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mauricette Brocco
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Françoise Lejeune
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Florence Serres
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Trevor Sharp
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Annie Daszuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Amélie Soumier
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mariusz Papp
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jean-Michel Rivet
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Gunnar Flik
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Thomas I. Cremers
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Olivier Muller
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Gilbert Lavielle
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Mark J. Millan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne Dekeyne.

Additional information

Requests for S32006 must forwarded in writing to Dr Mark J. Millan at the above address.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dekeyne, A., Mannoury la Cour, C., Gobert, A. et al. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology 199, 549–568 (2008). https://doi.org/10.1007/s00213-008-1177-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-008-1177-9

Keywords

Search

Navigation